What is Non-Toxigenic C. difficile (NTCD)?
Non-toxigenic Clostridioides difficile (NTCD) refers to strains of C. difficile bacteria that lack the genes encoding toxins A and B, making them incapable of causing C. difficile infection (CDI) since disease requires toxin production. 1
Key Characteristics
NTCD strains are non-pathogenic because CDI is fundamentally a toxin-mediated disease requiring production of toxins A and/or B 1, 2. These strains:
- Lack the pathogenicity locus (PaLoc), the chromosomal region containing toxin genes 3
- Still produce glutamate dehydrogenase (GDH), an enzyme common to both toxigenic and non-toxigenic strains 1
- Can colonize the human gastrointestinal tract without causing symptoms 4
Clinical Significance
Protective Effect
Colonization with NTCD strains may actually protect against CDI caused by toxigenic strains 2. The 2019 WSES guidelines note that patients colonized by non-toxigenic strains may be protected from developing CDI 2. This protective mechanism likely involves:
- Competition for nutrients and mucosal binding sites 5
- Occupying the ecological niche that would otherwise be filled by toxigenic strains 4
Diagnostic Implications
Standard CDI diagnostic tests cannot distinguish between NTCD colonization and toxigenic C. difficile infection, which creates important clinical challenges:
- GDH enzyme immunoassays detect both toxigenic and non-toxigenic strains, requiring a second confirmatory toxin test 1, 2
- Nucleic acid amplification tests (NAATs) detecting toxin genes will be negative for NTCD 2
- Specialized qPCR assays have been developed specifically to detect NTCD strains 6
Prevalence
Recent research found NTCD colonization in approximately 7% of hospitalized patients tested for CDI 6. Among patients with positive GDH but negative toxin tests, 20% harbored NTCD strains 6.
Important Caveats
A critical concern is that non-toxigenic strains can potentially convert to toxin producers through horizontal gene transfer 2, 3. Laboratory studies have demonstrated that the PaLoc can be transferred from toxigenic to non-toxigenic strains, converting them into toxin producers 3. This makes risk assessment of NTCD colonization challenging 2.
Therapeutic Potential
NTCD strains are being investigated as live biotherapeutic products to prevent CDI 7, 4, 8. Clinical trials are ongoing to evaluate their use for CDI prevention, though evidence for therapeutic efficacy in humans remains limited 4. A recent randomized trial demonstrated that NTCD colonization can be safely established in healthy volunteers, particularly after vancomycin pretreatment 8.
Clinical Bottom Line
Do not treat NTCD colonization with antibiotics—these patients are not infected and may actually be protected from developing true CDI 2. Testing should only be performed in symptomatic patients with diarrhea, as laboratory tests cannot distinguish colonization from infection 9.